Biotechnology - Anti-virals, Research

Filter

Current filters:

Anti-viralsResearch

Popular Filters

1 to 25 of 62 results

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

Janssen and Gilead expand agreement to develop HIV single-tablet regimen

Janssen and Gilead expand agreement to develop HIV single-tablet regimen

29-12-2014

US health care giant Johnson & Johnson’s Ireland-based subsidiary Janssen R&D Ireland has amended its…

Anti-viralsBiotechnologyCompleraEuropeGileadJanssenPrezistaResearchTybost

NewLink Genetic and Merck Ebola collaboration gets $30 million government award

23-12-2014

US biotech firm NewLink Genetics saw its shares gain 4.1% to $40.11 in morning trading on Monday, following…

Anti-viralsBiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesUSA

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

16-12-2014

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have…

Anti-viralsBiotechnologyCMC BiologicsOncoSynergyOS2966ProductionResearchTropical diseases

US declaration under PREP Act to support Ebola vaccines development

10-12-2014

US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

Scripps Research Institute scientists reveal weak spots in Ebola's defenses

18-11-2014

Scientists at The Scripps Research Institute (TSRI) have identified weak spots on the surface of Ebola…

Anti-viralsBiotechnologyMapp BiopharmaceuticalResearchTropical diseasesZMapp

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

31-10-2014

The US Department of Defense has contracted the manufacture and IND-enabling preclinical testing of the…

Anti-viralsBiotechnologyProfectus BioSciencesResearchUSAVesiculoVax Zaire-Ebola

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

09-10-2014

Antiviral biopharma company Chimerix has reported preliminary data indicating that its investigational…

Anti-viralsBiotechnologybrincidofovirChimerixResearchUSA

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

06-10-2014

AfriCoLeish, the international research and development consortium formed by six research organizations…

AfriCoLeishAmbisomeAnti-viralsBiotechnologyEthiopiaGilead SciencesResearch

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

Tekmira Pharma in focus as the world awaits Ebola treatment

Tekmira Pharma in focus as the world awaits Ebola treatment

06-08-2014

The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed many hundreds…

Anti-viralsBCX4430BioCryst PharmaceuticalsBiotechnologyEbolaMapp BiopharmaceuticalResearchRest of the WorldTekmira PharmaceuticalsTKM-EbolaUSA

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

10-06-2014

US drugmaker Achillion has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for…

ACH-3422AchillionAnti-viralsBiotechnologyRegulationResearchsovaprevir

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

1 to 25 of 62 results

COMPANY SPOTLIGHT

Menarini

Back to top